Cancer Chemotherapy and Pharmacology

, Volume 68, Issue 6, pp 1595–1602

A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202

  • Syma Iqbal
  • Cathryn Rankin
  • Heinz-Josef Lenz
  • Philip J. Gold
  • Syed A. Ahmad
  • Anthony B. El-Khoueiry
  • Michael J. Messino
  • Randall F. Holcombe
  • Charles D. Blanke
Original Article

DOI: 10.1007/s00280-011-1657-1

Cite this article as:
Iqbal, S., Rankin, C., Lenz, H. et al. Cancer Chemother Pharmacol (2011) 68: 1595. doi:10.1007/s00280-011-1657-1

Abstract

Purpose

Patients with gallbladder cancer or cholangiocarcinoma were treated with the combination of gemcitabine 1,000 mg/m2 IV over 100 min on days 1 and 8 and capecitabine 650 mg/m2 BID PO on days 1–14, administered every 21 days.

Methods

The primary objective of this study was to assess the response rate (confirmed complete and partial responses) of gemcitabine and capecitabine used in advanced/metastatic biliary neoplasms. Secondary objectives included overall survival and toxicities.

Results

The study accrued 57 patients from September 2003 to April 2005. Three patients were ineligible, and two others received no treatment. Characteristics of analyzable patients: 35 (67%) cholangiocarcinoma, 17 (33%) gallbladder cancer; PS 0 (18 pts), 1 (26 pts), 2 (8 pts); 26 (50%) men; median age 58.8 years (29.5–85.6). Among 51 patients evaluated for toxicity, 6 experienced grade 4 toxicities. Among 52 patients, there were 7 confirmed partial responses for a confirmed response probability of 13% (95% CI: 6–26%). Six patients had an unconfirmed partial response for an overall response probability of 25% (95% CI: 14–39%). Twelve patients (23%) demonstrated stable disease. The 6-month overall survival was 55% (95% CI: 41–69%), and median survival was 7 months (95% CI: 5–8 months).

Conclusions

The combination of gemcitabine and capecitabine is a well-tolerated regimen with activity in patients with advanced gallbladder cancer and cholangiocarcinoma.

Keywords

GemcitabineCapecitabineCholangiocarcinomaGallbladderClinical trial

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Syma Iqbal
    • 1
  • Cathryn Rankin
    • 2
  • Heinz-Josef Lenz
    • 1
  • Philip J. Gold
    • 3
  • Syed A. Ahmad
    • 4
  • Anthony B. El-Khoueiry
    • 1
  • Michael J. Messino
    • 5
  • Randall F. Holcombe
    • 6
  • Charles D. Blanke
    • 7
  1. 1.Norris Comprehensive Cancer CenterUniversity of Southern CaliforniaLos AngelesUSA
  2. 2.Southwest Oncology Group Statistical CenterSeattleUSA
  3. 3.Swedish Cancer InstituteSeattleUSA
  4. 4.Barrett Center, Department of SurgeryUniversity of CincinnatiCincinnatiUSA
  5. 5.Southeast Cancer Control Consortium, Inc. CCOP, Cancer Care of WNCAshevilleUSA
  6. 6.University of California at Irvine, Chao Family CCCOrangeUSA
  7. 7.University of British Columbia, and British Columbia Cancer AgencyVancouverCanada